Esther P. B. Rodman

Antibody–drug conjugates for advanced/recurrent high-grade endometrial cancer: potential targets, strategies and challenges

The incidence of endometrial cancer is on the rise, along with a concurrent increase in mortality. For advanced-stage endometrial cancer, standard treatment regimens include surgery, radiation, and cytotoxic chemotherapy; however, options are limited in the recurrent disease setting. Antibody–drug conjugates (ADCs) hav...